| 1 |
中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700.
|
|
Chinese Hypertension Prevention and Treatment Guidelines Revision Committee, Chinese Hypertension League, Branch of Hypertension, China International Exchange and Promotive Association for Medical and Health Care, et al. Chinese guidelines for the prevention and treatment of hypertension (revised 2024 edition)[J]. Chinese Journal of Hypertension, 2024, 32(7): 603-700.
|
| 2 |
HAMRAHIAN S M. Management of hypertension in patients with chronic kidney disease[J]. Curr Hypertens Rep, 2017, 19(5): 43.
|
| 3 |
ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822.
|
| 4 |
SEKI T, SAITA E, KISHIMOTO Y, et al. Low levels of plasma osteoglycin in patients with complex coronary lesions[J]. J Atheroscler Thromb, 2018, 25(11): 1149-1155.
|
| 5 |
FANG Y, CHANG Z, XU Z, et al. Osteoglycin silencing exerts inhibitory effects on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation in a mouse model of myocarditis[J]. Biofactors, 2020, 46(6): 1018-1030.
|
| 6 |
CHENG J M, AKKERHUIS K M, MEILHAC O, et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5): 1078-1084.
|
| 7 |
GU X, ZHAO L, ZHU J, et al. Serum mimecan is associated with arterial stiffness in hypertensive patients[J]. J Am Heart Assoc, 2015, 4(7): e002010.
|
| 8 |
ZUO Z, LI M H, ZHENG X H, et al. Elevated plasma levels of osteoglycin in cardiovascular patients: a systematic review and meta-analysis[J]. Ann Palliat Med, 2022, 11(2): 498-505.
|
| 9 |
WANG S, WANG Y, ZHENG R, et al. Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy[J]. Int J Clin Exp Pathol, 2015, 8(3): 3110-3115.
|
| 10 |
STEVENS L A, CORESH J, GREENE T, et al. Assessing kidney function: measured and estimated glomerular filtration rate[J]. N Engl J Med, 2006, 354(23): 2473-2483.
|
| 11 |
ZHU Y, YE X, ZHU B, et al. Comparisons between the 2012 new CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations and other four approved equations[J]. PLoS One, 2014, 9(1): e84688.
|
| 12 |
LEVEY A S, STEVENS L A, SCHMID C H, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612.
|
| 13 |
HUANG Q F, CHENG Y B, GUO Q H, et al. Serum galectin-3 and mucin-1 (CA15-3) in relation to renal function in untreated Chinese patients[J]. Am J Hypertens, 2023, 36(3): 176-182.
|
| 14 |
NULALI J, ZHAN M, ZHANG K, et al. Osteoglycin: an ECM factor regulating fibrosis and tumorigenesis[J]. Biomolecules, 2022, 12(11): 1674.
|
| 15 |
YANG Y, WU Q H, LI Y, et al. Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients[J]. J Hum Hypertens, 2018, 32(8/9): 564-571.
|
| 16 |
TENGRYD C, NIELSEN S H, CAVALERA M, et al. The proteoglycan mimecan is associated with carotid plaque vulnerability and increased risk of future cardiovascular death[J]. Atherosclerosis, 2020, 313: 88-95.
|
| 17 |
ZUO C, LI X, HUANG J, et al. Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling[J]. Cardiovasc Res, 2018, 114(5): 703-712.
|
| 18 |
STAKHNEVA E M, MESHCHERYAKOVA I A, DEMIDOV E A, et al. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis[J]. Diagnostics (Basel), 2019, 9(4): 177.
|
| 19 |
AL-SHARIFY D, NIELSEN S H, MATTHES F, et al. Increased proteolytic cleavage of osteoglycin is associated with a stable plaque phenotype and lower risk of cardiovascular events[J]. Atherosclerosis, 2022, 355: 8-14.
|
| 20 |
KUNNATHATTIL M, RAHUL P, SKARIA T. Soluble vascular endothelial glycocalyx proteoglycans as potential therapeutic targets in inflammatory diseases[J]. Immunol Cell Biol, 2024, 102(2): 97-116.
|
| 21 |
WEI W, TU M, HUANG R, et al. Serum osteoinductive factor is associated with microalbuminuria and diabetic nephropathy in type 2 diabetes[J]. Medicine (Baltimore), 2018, 97(31): e11759.
|
| 22 |
GONZÁLEZ-SALVATIERRA S, GARCÍA-FONTANA C, ANDÚJAR-VERA F, et al. Osteoglycin as a potential biomarker of mild kidney function impairment in type 2 diabetes patients[J]. J Clin Med, 2021, 10(10): 2209.
|
| 23 |
SCHIFFRIN E L, POLLOCK D M. Endothelin system in hypertension and chronic kidney disease[J]. Hypertension, 2024, 81(4): 691-701.
|
| 24 |
BARTON M, YANAGISAWA M. Endothelin: 30 years from discovery to therapy[J]. Hypertension, 2019, 74(6): 1232-1265.
|
| 25 |
PENG T, LI X, HU Z, et al. Predictive role of endothelin in left ventricular remodeling of chronic kidney disease[J]. Ren Fail, 2018, 40(1): 183-186.
|
| 26 |
REBHOLZ C M, HARMAN J L, GRAMS M E, et al. Association between endothelin-1 levels and kidney disease among blacks[J]. J Am Soc Nephrol, 2017, 28(11): 3337-3344.
|
| 27 |
FISCHER A, BOSSARD M, AESCHBACHER S, et al. Plasma levels of endothelin-1 and renal function among young and healthy adults[J]. Clin Chem Lab Med, 2017, 55(8): 1202-1208.
|